NVIDIA
NVDA
Tesla
TSLA
Taiwan Semiconductor
TSM
4
Palantir
PLTR
5
Super Micro Computer
SMCI
US Stock MarketDetailed Quotes
GBIO Generation Bio
- 0.528
- -0.010-1.79%
Close Mar 4 16:00 ET
- 0.519
- -0.009-1.67%
Post 17:39 ET
35.23MMarket Cap-0.24P/E (TTM)
0.574High0.510Low396.26KVolume0.520Open0.537Pre Close213.07KTurnover0.82%Turnover RatioLossP/E (Static)66.79MShares4.65052wk High0.34P/B25.62MFloat Cap0.51052wk Low--Dividend TTM48.57MShs Float55.720Historical High--Div YieldTTM11.84%Amplitude0.510Historical Low0.537Avg Price1Lot Size
Generation Bio Stock Forum
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If yo...
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
Monday, 6th January at 4:30 pm
•Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo
•Programs to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven autoimmune diseases
•Company reorganization supports evolution of ctLNP-enabled strategy and b...
NEWS
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
Positive
Generation Bio's presentation at the ASGCT highlights significant advancements in iqDNA technology and ctLNP delivery systems, showcasing the company's commitment to innovation in genetic medicine.
The rapid enzymatic synthesis process utilized by Generation Bio enhances the performance of iqDNA, providing a potential breakthrough in ...
NEWS
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Generation Bio Co. will present six abstracts at the ASGCT 27th Annual Meeting.
The abstracts will highlight preclinical data from the company's ctLNP and iqDNA platforms.
One of the presentations will focus on highly specific, in vivo delivery to T-cells with cell-targeted lipid nanoparticles.
The c...
No comment yet